Cancer Research Aziza Shad  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Song, Z.
Right arrow Articles by Roy-Burman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, Z.
Right arrow Articles by Roy-Burman, P.
[Cancer Research 60, 6730-6736, December 1, 2000]
© 2000 American Association for Cancer Research


Tumor Biology

The Effect of Fibroblast Growth Factor 8, Isoform b, on the Biology of Prostate Carcinoma Cells and Their Interaction with Stromal Cells1

Zhigang Song, William C. Powell, Noriyuki Kasahara, Adriaan van Bokhoven, Gary J. Miller and Pradip Roy-Burman2

Departments of Pathology [Z. S., W. C. P., N. K., P. R-B.], and Biochemistry and Molecular Biology [N. K., P. R-B.], University of Southern California, Keck School of Medicine, Los Angeles, California 90033, and Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262 [A. v. B., G. J. M.]

Fibroblast growth factor 8, isoform b (FGF8b), has been implicated in the oncogenesis of the prostate and mammary epithelia. We examined whether overexpression of FGF8b in a weakly tumorigenic prostate carcinoma cell line, LNCaP, could alter the growth and tumorigenic properties of these cells. LNCaP cells were infected with a lentivirus vector carrying FGF8b cDNA and the green fluorescent protein (GFP) cDNA in the same construct, and the infected cell population was sorted on the basis of GFP protein expression. It was demonstrated that, in comparison with the cells transduced with GFP-vector alone, LNCaP cells with FGF8b-GFP expression manifested an increased growth rate, higher soft agar clonogenic efficiency, enhanced in vitro invasion, and increased in vivo tumorigenesis. Most strikingly, whereas parental or vector-control LNCaP cells failed to grow at all in an in vivo tumorigenesis/diaphragm invasion assay in nude mice, the cells overexpressing FGF8b proliferated as deposits of tumor cells on the diaphragm, frequently with indications of tumor cell invasion into the diaphragm. Coculturing of primary prostatic or non-prostatic stromal cells with the infected LNCaP cells led us to observe that: (a) stromal cells, irrespective of tissue origin, strongly suppressed LNCaP cell growth; (b) FGF8b producing LNCaP cells could partially evade the stromal inhibition, perhaps from the autocrine stimulatory effect of FGF8b; and (c) production of FGF8b in the coculture had a stimulatory effect on the proliferation of the stromal cells, prostatic or non-prostatic. This stimulation was not attributable to the direct action of FGF8b on stromal cells. Instead, it appears that epithelial-stromal cell-cell contact and some unknown soluble factors secreted by LNCaP cells upon stimulation of FGF8b are required for the maximal effect. Together, these results suggest that the growth rate and biological behavior of prostatic cancer cells can be altered to a more aggressive phenotype by up-regulation of FGF8b expression. These changes in phenotype also influence the interaction of the affected cells with stromal cells. The data obtained may have direct relevance to the progression of prostate cancer, recognizing that FGF8b is naturally overexpressed in advanced disease.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Yang, M. Lim, L. K. Pham, S. E. Kendall, A. H. Reddi, D. C. Altieri, and P. Roy-Burman
Bone Morphogenetic Protein 7 Protects Prostate Cancer Cells from Stress-Induced Apoptosis via Both Smad and c-Jun NH2-Terminal Kinase Pathways.
Cancer Res., April 15, 2006; 66(8): 4285 - 4290.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Zhong, G. Saribekyan, C.-P. Liao, M. B. Cohen, and P. Roy-Burman
Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis
Cancer Res., February 15, 2006; 66(4): 2188 - 2194.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P. S. Nelson, and P. Roy-Burman
Increased Expression of Osteopontin Contributes to the Progression of Prostate Cancer
Cancer Res., January 15, 2006; 66(2): 883 - 888.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
S. Hagisawa, C. Ohyama, T. Takahashi, M. Endoh, T. Moriya, J. Nakayama, Y. Arai, and M. Fukuda
Expression of core 2 {beta}1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression
Glycobiology, October 1, 2005; 15(10): 1016 - 1024.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Yang, C. Zhong, B. Frenkel, A. H. Reddi, and P. Roy-Burman
Diverse Biological Effect and Smad Signaling of Bone Morphogenetic Protein 7 in Prostate Tumor Cells
Cancer Res., July 1, 2005; 65(13): 5769 - 5777.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Shimada, T. Ishii, T. Imada, K. Takaba, Y. Sasaki, K. Maruyama-Takahashi, Y. Maekawa-Tokuda, H. Kusaka, S. Akinaga, A. Tanaka, et al.
A Neutralizing Anti-Fibroblast Growth Factor 8 Monoclonal Antibody Shows Potent Antitumor Activity against Androgen-Dependent Mouse Mammary Tumors In vivo
Clin. Cancer Res., May 15, 2005; 11(10): 3897 - 3904.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Ishibe, T. Nakayama, T. Okamoto, T. Aoyama, K. Nishijo, K. R. Shibata, Y. Shima, S. Nagayama, T. Katagiri, Y. Nakamura, et al.
Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy
Clin. Cancer Res., April 1, 2005; 11(7): 2702 - 2712.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
B Kwabi-Addo, M Ozen, and M Ittmann
The role of fibroblast growth factors and their receptors in prostate cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Song, X. Wu, W. C. Powell, R. D. Cardiff, M. B. Cohen, R. T. Tin, R. J. Matusik, G. J. Miller, and P. Roy-Burman
Fibroblast Growth Factor 8 Isoform b Overexpression in Prostate Epithelium: A New Mouse Model for Prostatic Intraepithelial Neoplasia
Cancer Res., September 1, 2002; 62(17): 5096 - 5105.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.